VANCOUVER, British Columbia, June 16, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, has closed its previously announced public offering of 1,789,900 units for total gross proceeds before expenses of CDN$5.1 million. The Company intends to use the net proceeds of the offering for general corporate purposes.
